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Abstract
Background: T cells recognize a complex between a specific major histocompatibility complex
(MHC) molecule and a particular pathogen-derived epitope. A given epitope will elicit a response
only in individuals that express an MHC molecule capable of binding that particular epitope. MHC
molecules are extremely polymorphic and over a thousand different human MHC (HLA) alleles are
known. A disproportionate amount of MHC polymorphism occurs in positions constituting the
peptide-binding region, and as a result, MHC molecules exhibit a widely varying binding specificity.
In the design of peptide-based vaccines and diagnostics, the issue of population coverage in relation
to MHC polymorphism is further complicated by the fact that different HLA types are expressed
at dramatically different frequencies in different ethnicities. Thus, without careful consideration, a
vaccine or diagnostic with ethnically biased population coverage could result.
Results: To address this issue, an algorithm was developed to calculate, on the basis of HLA
genotypic frequencies, the fraction of individuals expected to respond to a given epitope set,
diagnostic or vaccine. The population coverage estimates are based on MHC binding and/or T cell
restriction data, although the tool can be utilized in a more general fashion. The algorithm was
implemented as a web-application available at http://epitope.liai.org:8080/tools/population.
Conclusion: We have developed a web-based tool to predict population coverage of T-cell
epitope-based diagnostics and vaccines based on MHC binding and/or T cell restriction data.
Accordingly, epitope-based vaccines or diagnostics can be designed to maximize population
coverage, while minimizing complexity (that is, the number of different epitopes included in the
diagnostic or vaccine), and also minimizing the variability of coverage obtained or projected in
different ethnic groups.
Background
T lymphocytes recognize a complex between a specific
major histocompatibility complex (MHC) molecule and a
particular pathogen-derived epitope. Thus, a given
epitope will elicit a response only in individuals that
express an MHC molecule capable of binding that partic-
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ular epitope, explaining to a large extent the phenomenon
known as "MHC restriction" [1]. In humans, MHC mole-
cules are known as human leukocyte antigen (HLA) mol-
ecules and two different types exist: class I and class II.
HLA class I molecules mostly bind peptides derived from
the endogenous processing pathway, and their recogni-
tion is primarily associated with cytotoxic T lymphocytes
(CTL), which are most important for antiviral and anti-
cancer immunity responses. By contrast, HLA class II mol-
ecules bind peptides typically derived from the
extracellular milieu, and they are important for helper T
lymphocyte (HTL) responses, which regulate antibody
and cytotoxic responses.
HLA molecules are extremely polymorphic. Over a thou-
sand different HLA allelic variants have been defined to
date [2]. Specific HLA alleles are expressed at dramatically
different frequencies in different ethnicities [3,4]. There-
fore, in the design and development of T-cell epitope-
based diagnostics or vaccines, selecting multiple epitopes
with different HLA binding specificities will afford
increased coverage of the patient population. A pertinent
goal, in this context, might be to identify optimal sets of
HLA alleles with maximal coverages for different popula-
tions [5,6]. Extensive analyses by Longmate and cowork-
ers [7] suggested that 90% population coverage of several
ethnic groups can be achieved by targeting eleven differ-
ent HLA molecules. However, 90% coverage of African
and Asian ethnicities required four or more additional
molecules. Dawson et al. also analyzed the problem [8]
and concluded that to reach 80% coverage, 3 to 5 HLA
molecules were required in a given ethnicity, but the
actual HLA specificities required were different in different
ethnic groups.
An important consideration in the process of epitope
selection for a T-cell epitope-based diagnostic or vaccine is
that the patient population coverage afforded by a given
epitope set does not simply correspond to the sum of the
coverage of the individual components. To calculate the
coverage afforded by a given set of epitopes with multiple
and/or overlapped HLA binding specificities, a more com-
prehensive approach, taking into account MHC binding
and T cell recognition patterns, is required for this pur-
pose. A suitable algorithm was previously utilized [9-11]
but not described in detail. This method calculates the
fraction of individuals predicted to respond to a given
epitope or epitope set on the basis of HLA genotypic fre-
quencies and on the basis of MHC binding and/or T cell
restriction data. In this paper, we describe the algorithm
and its implementation as a web application available to
the public. We believe this is a useful tool to aid in the
design and development of T-cell epitope-based diagnos-
tics and vaccines intended to be effective across diverse
populations.
Implementation
For a given HLA gene locus, let {m1, m2, ..., mN} denote a
set of MHC alleles, with each allele associated with a gen-
otypic frequency G(mi) for a population or ethnic group.
To account for 100% of alleles of a given locus, the total
genotypic frequency (∑G(mi)) should add up to 1. If
∑G(mi) is less than 1, an unidentified HLA allele with a
genotypic frequency equal to the residual (1 - ∑G(mi)) is
added to the locus. If ∑G(mi) is greater than 1, the geno-
typic frequency of each mi allele of the locus is scaled
down proportionately by dividing the frequency by
∑G(mi). Next, let {e1, e2, ..., eK} denote a set of epitopes
with known MHC binding or restriction data. For each
epitope ek, its restriction to an MHC allele mi, ek(mi), is
defined as followed:
First, for each MHC allele (mi), a total number of epitope
"hits",  H(mi), was tabulated by adding the number of
epitopes that are restricted to (or bound by) mi:
Next, for each possible diploid MHC combination (mi,
mj), a phenotypic frequency F(mi, mj) was calculated based
on individual allele genotypic frequency:
F(mi, mj) = G(mi) × G(mj)   (3)
For n MHC types, this corresponds to an n × n tabulation
of the phenotypic frequency at which each specific pair of
MHCs will be found in the population from which the
MHC frequencies were derived. A similar table was also
generated to contain the number of epitope hits per each
of the MHC combinations H(mi, mj). In the case of heter-
ozygous combinations, H(mi, mj) was calculated as the
sum of the number of epitope hits associated with each of
the two alleles, H(mi) + H(mj). This is because mi and mj
are two different alleles, and therefore the number of
epitope hits recognized by each allele in the combination
is independent of each other. However, in the case of
homozygous combinations which contain two identical
alleles, the number of epitope hits was the same as the
number of epitope hits of the given allele:
Based on the calculated F(mi, mj) and H(mi, mj) tables, a
frequency distribution was assembled by tabulating the
phenotypic frequencies of all MHC combinations associ-
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ated with a certain number of epitope/HLA combination
hits (h):
where   is an indica-
tor function.
For calculation of coverage by epitope sets restricted to
MHC alleles of multiple k different loci, a combined fre-
quency distribution (P) as a function of epitope/HLA
combination hits (n) was generated by merging k separate
frequency distributions. This merging procedure is based
on the assumption that linkages between MHC loci are in
equilibrium, and was done as follows:
where   is an indicator func-
tion, and Fi(hi) is a phenotypic frequency associated with
hi epitope/HLA combination hits of locus i  calculated
from equation 5.
The population coverage (C) or fraction of individuals
projected to respond to the epitope set was then calcu-
lated as the sum of the combined phenotypic frequencies
associated with at least one epitope hit/HLA combination:
Based on equation 6, a histogram was generated to sum-
marize the fraction of population coverage (P) as a func-
tion of the number of HLA/epitope combinations (n)
recognized. A cumulative population coverage distribu-
tion frequency (Y) as a function of the number of HLA/
epitope combinations (n) was also calculated:
From this cumulative population coverage distribution of
the whole epitope set, PC90, defined as the minimum
number of epitope/HLA combination hits (n) recognized
by 90% of the population, was determined as follow:
where Y(n) ≥ 0.9 > Y(n + 1). Because) PC90 was deter-
mined by data interpolation, it can be of any positive dec-
imal value. Based on equation 9, if the population
coverage is less than 90% or  ,
PC90 will be less than 1.
Additionally, the average number of epitope/HLA combi-
nation hits (A) recognized by the population is a weighted
average and was calculated as follow:
Results and discussions
The Population Coverage Calculation program was
implemented as a Java servlet public web-application (see
Availability and Requirements section). HLA allele (geno-
typic) frequencies were obtained from dbMHC database
[12]. At present, dbMHC database provides allele frequen-
cies for 78 populations grouped into 11 different geo-
graphical areas. In addition to the allele frequencies
obtained from the dbMHC database, the Population Cov-
erage Calculation program also accepts custom popula-
tions with allele frequencies defined by users. Multiple
population coverages can be simultaneously calculated
and an average population coverage is generated. Since
MHC class I and MHC class II restricted T cell epitopes
elicit immune responses from two different T cell popula-
tions (CTL and HTL, respectively), the program provides
three calculation options to accommodate different cover-
age modes – (1) class I separate, (2) class II separate, and
(3) class I and class II combined. For each population cov-
erage, a histogram is generated to summarize the percent-
age distribution of individuals as a function of the
number of epitope/HLA combinations recognized. A
cumulative coverage distribution plot is also generated to
determine the minimum number of epitope/HLA combi-
nations recognized by 90% of the population (PC90).
Finally, the average number of epitope/HLA combina-
tions recognized by the population and coverages of indi-
vidual epitope are also calculated.
It should be noted that when population coverages are
projected from an epitope set restricted to alleles from
multiple HLA loci, linkages between loci are taken into
account. The overall population (phenotypic frequency),
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(Ptotal), is mathematically derived as the sum of the indi-
vidual locus' coverage corrected for the overlaps:
, where Pij is the frequency of the ij hap-
lotype, Pijk is the frequency of the ijk haplotype, etc... If
gene linkage equilibrium is assumed, Pij can be calculated
as the product of the individual allele phenotypic frequen-
cies (Pi × Pj), and Pijk = Pi × Pj × Pk, etc... This calculation is
implicitly incorporated in our current algorithm (equa-
tion 6). However, if gene linkage is in disequilibrium, the
frequency of a given haplotype is usually not equal to the
product of their individual allele phenotypic frequencies,
(Pij ≠ Pi × Pj, Pijk ≠ Pi × Pj × Pk, ...). As a result, to account for
linkage disequilibrium between HLA loci, complete data
on haplotype frequencies must be known. Therefore, it
would be difficult to factor in linkage disequilibrium at
this time because linkage disequilibrium is known to be
different in different ethnicities, and data regarding the
specific disequilibrium in different ethnicities in general is
not available or incomplete. As more comprehensive
MHC linkage disequilibrium data becomes available, our
method can be modified to incorporate this type of calcu-
lation.
Although the present program assumes linkage equilib-
rium between HLA loci, the impact of linkage disequilib-
rium, which is known to occur in the MHC region, on the
calculated coverage is expected, in most contexts, to be
minimal. For example, in the North American Caucasian
population, the A1 and B8 antigens of HLA-A and -B loci,
respectively, are known to be the strongest linked antigen
pair with an observed haplotype frequency of 7.95% [13].
The genotypic frequencies of the A1 and B8 antigens are
15.18% and 9.41%, respectively [13]. Assuming the link-
age between A1 and B8 antigens is in equilibrium, the
overall population coverage calculated by the present pro-
gram is 40.97%, and the individual population coverages
by A1 and B8 antigens are 28.06% and 17.93%, respec-
tively. The expected equilibrium frequency for the A1/B8
haplotype, in this case, is 5.03% (28.06% × 17.93%)
which is 2.92% less than the observed frequency of
7.95%. Therefore, if linkage disequilibrium is considered,
the overall population coverage will be 38.04% (28.06%
+ 17.93% - 7.95%). Thus, even for the most tightly linked
A1/B8 haplotype in the Caucasian population, linkage
disequilibrium, in this specific example, only accounted
for less than 3% difference in the population coverage cal-
culated by the present program. Furthermore, we have
also investigated the deviations between the observed and
expected equilibrium frequencies of 1012 HLA-A/-B hap-
lotypes in the North American Caucasian population,
based on available antigen- and haplotype-frequencies
published by Mori et al. [14,15]. On average, the observed
haplotype frequencies deviated from the expected equilib-
rium frequencies by approximately 0.58%. As a result,
linkage disequilibrium is expected to impact the calcu-
lated population coverage, but the degree of the impact is
expected to be negligible.
It should be pointed out that the calculations described
herein can also be performed on data spreadsheets, but
the process is laborious, error prone and also requires
extensive immunological expertise. In our experience, a
single calculation without the aid of this tool requires sev-
eral hours to complete. To the best of our knowledge, at
this time, there is no existing program that is publicly
accessible as a web-resource that can offer the flexibility
and range of utility similar to the Population Coverage
Calculation program that we have developed. The present
application represents a significant enhancement of the
dbMHC database's utility by incorporating its compiled
data of world-wide ethnic population frequencies to cal-
culate HLA coverage for user-defined population subsets.
The program is flexible by allowing the user to specify
groups of related or unrelated ethnicities as well as specify
the HLA alleles under consideration. Additional flexibility
features include the implementation of separate calcula-
tions for both MHC Class I and Class II demarcated recog-
nitions as they involve immune responses from two
different populations of T cells – CTL and HTL, respec-
tively. The output of the program was also specifically
designed to be accessible to both specialists and neo-
phytes in the field of MHC research. Therefore, having this
tool publicly available is highly desirable. Additionally, in
our future works, we plan to incorporate in the tool the
ability to search for minimal epitope subset(s) within the
given epitope set that will afford a specified population
coverage level. This is not a trivial task due to a large
number of possible epitope subsets (S) that has to be con-
sidered,   where  n is the total number of
epitopes and k is the number of epitopes in a subset. For
example, for a set of 20 epitopes, there will be a total of
1,048,575 combinations of epitope subsets that needs to
be evaluated. Therefore, a strategic searching approach
must be devised to computationally accomplish this task.
In summary, with the help of this Population Coverage
Calculation program, epitope-based vaccines or diagnos-
tics can be designed to maximize population coverage
while minimizing complexity (that is, the number of dif-
ferent epitopes included in the diagnostic or vaccine), and
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also minimizing the variability of coverage obtained or
projected in different ethnic groups.
Conclusion
Herein, we have implemented a method to calculate pro-
jected population coverage of a T-cell epitope-based diag-
nostic or vaccine using MHC binding or T cell restriction
data and HLA gene frequencies. The Population Coverage
Calculation program was designed to be user friendly and
flexible. Besides the compiled HLA gene frequencies cur-
rently provided, users can also supply their own tabulated
HLA gene frequencies for calculation. Therefore, research-
ers can use this tool to perform coverage analyses on their
specific patient populations. We plan to continuously
update the compiled HLA gene frequencies as more data
are available, and thus to provide researchers with a useful
tool to aid in the design and development of effective T-
cell epitope-based diagnostics and vaccines.
Availability and requirements
Project name: Population Coverage Calculation
Project home page: http://epitope.liai.org:8080/tools/
population
Programming language: Java
Operating system: Fedora Linux
Other requirements: Apache Tomcat 5.5.12, MySQL 4.1
Web browser: Population Coverage Calculation program
has been tested and shown to work with the following
browsers: Firefox version 1.5 (PC and Mac OS X), Net-
scape version 8.0.4 (PC), Netscape version 7.2 (Mac OS
X), Internet Explorer version 6.0 (PC), Internet Explorer
version 5.2 for Mac (Mac OS X). Default security settings
were used.
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